pharmaphorum

OCTOBER 6, 2020

The vaccine is based on different technology from AZ’s rival: while AZ’s uses a weakened and genetically modified cold virus to prime the immune system, BNT162b2 is based on a string of RNA.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

SEPTEMBER 30, 2021

. “We used NanoSTING because the adjuvant for intranasal vaccination and single-cell RNA-sequencing to verify the nasal-associated lymphatic tissue as an inductive site upon vaccination. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccination 52

Vaccination Vaccine Immune Response Licensing 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccination 52

Vaccination Vaccine Trials Protein 52

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Shots on goal in the fight against COVID-19. About Translate Bio.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

JUNE 25, 2021

The vaccine candidate chosen for first clinical development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). CureVac began development of mRNA-based COVID-19 vaccine candidates in January 2020.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

The Pharma Data

JULY 6, 2021

Fitusiran is an investigational, subcutaneously administered small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors and has the potential to transform treatment as it would be the only prophylactic therapy with as few as six injections per year. ePoster Abstract # OC48.2

Protein 52

Protein RNA Development Marketing 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Find Me Cure

OCTOBER 13, 2019

HER2 is a protein that plays an important role in cancer cell growth and is found on the surface of cancer cells in a very high quantity in about 10-20% of breast cancers. The team sequenced DNA and RNA from her tumour and from healthy tissue to find out which unique to her case mutations they needed to target.

Development 52

Development DNA Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 25, 2020

The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. 26, 2020 11:00 UTC. CAMBRIDGE, Mass.–(

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Development 52

The Pharma Data

JANUARY 13, 2021

The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan. The new vaccine is made up of a deactivated cold virus into which scientists cut-and-paste a genetic version of the “spike” protein used by the coronavirus to infect cells.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. ” In the same time period, mRNA vaccines were being deployed and immune responses to those vaccines were being studied.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

Camargo

JULY 27, 2021

As with any standard drug treatment, gene therapies carry potential risks, including adverse events, unexpected gene modification (activation or inactivation), undesired immune responses, or complications with the genetic material. Route of Administration Considerations.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body.

RNA 98

RNA Drugs Protein Immune Response 98

Pharmaceutical Technology

FEBRUARY 3, 2023

Now, the HIV research community is setting its sights on vaccines that are in earlier stages of development, based on new approaches like messenger RNA (mRNA) -based vaccines or those using human cytomegalovirus (HCMV) vectors. mRNA vaccines can be made and modified quickly compared to protein subunit vaccines, says Montefiore.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

pharmaphorum

AUGUST 31, 2021

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. The post ‘Endless RNA’ startup Laronde raises $440m to fuel pipeline appeared first on.

RNA 52

RNA Protein Immune Response Medicine 52

XTalks

JUNE 5, 2023

Abrysvo is an unadjuvanted vaccine and is composed of two preF proteins selected to optimize protection against RSV A and B strains. “A RSV belongs to the family of negative-strand RNA viruses and was first identified in 1955. The genetic material of RSV (respiratory syncytial virus) encodes 11 proteins.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

pharmaphorum

SEPTEMBER 14, 2021

Repeat sequences aren’t involved in expressing proteins so have been generally under-studied by researchers, but there is increasing evidence that some human traits and diseases may be associated with mutations within them. Most drug discovery programmes target the roughly 2% of the human genome which encodes for protein.

DNA 52

DNA Immune Response Genome Genomics 52

XTalks

MARCH 10, 2021

While molecular PCR-based tests remain the gold standard for the detection of SARS-CoV-2 viral RNA, rapid antigen tests are useful for screening purposes. The diagnostic test is a molecular nucleic acid amplification test (NAAT) that is intended to detect SARS-CoV-2 viral RNA from samples collected via nasopharyngeal swabbing.

Protein 98

Protein RNA Antibody Production 98

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

JANUARY 21, 2021

Luckily, the new variants still rely on the coronavirus’ “spike protein” to infect cells, and the two COVID vaccines now on the U.S. market specifically target the spike protein to prevent transmission, explained Dr. Kathryn Edwards, scientific director of the Vanderbilt University Vaccine Research Program in Nashville.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

pharmaphorum

SEPTEMBER 22, 2022

The beauty of that T-cell response is that you can actually access the internal parts of the virus,” Le Vert states. Osivax’s technology, oligoDOM, trains the T-cell immune response to recognise the nucleoprotein.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

Delveinsight

DECEMBER 13, 2020

The first approved treatment for hepatitis C was a series of protein-based injections called recombinant interferon-alfa (IFNa). Interferons are naturally occurring proteins in the body; recombinant IFNa is the protein-based drug that works to mobilize the body’s natural immune system to fight disease.

Genotype 52

Genotype FDA Approval DNA Drugs 52

pharmaphorum

NOVEMBER 4, 2022

The influenza virus is subject to constant mutations to evade host immune response, and this causes the seasonal variation in circulating strains. The follow-up period for each participant will be a total of six months.

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

The Pharma Data

MARCH 8, 2022

The virus carries the information to produce a series of proteins, capable of inhibiting antiviral recognition systems of the infected cell. Actually, these systems could identify viral genetic material (here: Ribonucleic acids/RNAs) and sound the alarm. Camouflage protects virus from immune system.

Immune Response 52

Immune Response RNA Protein Genetics 52

Pfizer

NOVEMBER 2, 2022

The first participant has been dosed in a Phase 1 trial evaluating the safety, tolerability, and immunogenicity of a nucleoside-modified RNA (modRNA)-based combination vaccine approach. Hemagglutinin is a surface protein of the influenza virus which plays a role in the initiation of infection. COMIRNATY® (COVID-19 Vaccine, mRNA).

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

pharmaphorum

JULY 6, 2021

PCR tests screen for the presence of viral RNA from a swab, detecting whether an individual is currently infected. Antibodies to the spike protein are termed ‘neutralising antibodies’, as they bind to the spike protein of SARS-CoV-2 and ‘neutralise’ the virus by interfering with its ability to enter human cells.

Antibody 111

Antibody Immune Response Protein Vaccination 111

The Pharma Data

DECEMBER 18, 2020

The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. The vaccine contains a small piece of the SARS-CoV-2 virus’s mRNA that instructs cells in the body to make the virus’s distinctive “spike” protein. Director of the FDA’s Center for Biologics Evaluation and Research.

Vaccination 52

Vaccination Vaccine Production Manufacturing 52

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

Pharmaceutical Technology

NOVEMBER 22, 2022

Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease. When an mRNA vaccine is administered, a patient’s body produces that protein to prompt a desired immune response. million in funding to support this work.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

Delveinsight

SEPTEMBER 23, 2021

Boehringer stated that the Abexxa’s generation aims at cancer-specific proteins situated throughout the mobile versus proteins at the mobile membrane broadening the selection of possible cancer antigen objectives. 858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Jeffrey Stafford, Ph.D.,

RNA 61

RNA Gene Therapy Gene Protein 61

The Pharma Data

AUGUST 3, 2021

The company and MiNA Therapeutics Limited announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. The company announced the acquisition of Protomer Technologies Inc., Loxo Oncology at Lilly and Kumquat Biosciences Inc.

Antibody 52

Antibody Sales Development Production 52

pharmaphorum

JANUARY 17, 2023

Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution. As it stands, mRNA vaccines and therapeutics can only provide benefits if they can reach the living cells and be processed into protein.

Vaccination 97

Vaccination Vaccine In-Vivo In-Vitro 97

Roots Analysis

AUGUST 23, 2024

Unveiling The Potential of mRNA Technology mRNA is a single-stranded molecule that relays the genetic instructions needed to make proteins from DNA in the cell nucleus to ribosomes. Ribosomes are cellular machines that read mRNA sequences and produce proteins. There are several advantages to approaching vaccination this way.

Protein 40

Protein Vaccination Vaccine Immune Response 40

The Pharma Data

MAY 17, 2021

The investigational COVID-19 vaccine uses the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines, along with GSK’s established pandemic adjuvant technology. The interim results from the phase 2 trial on the vaccine, published today, on the contrary, showed a “ strong neutralizing antibody response” ?

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52